非酒精性脂肪肝病药物研究进展

Advances in Drug Research for Nonalcoholic Fatty Liver Disease

非酒精性脂肪肝病(Nonalcoholic fatty liver disease,NAFLD)正在成为全球主要的慢性肝病,可引起肝硬化、肝癌等终末期肝病。NAFLD是多系统代谢疾病,与肝外器官疾病联系密切,其发病机制复杂,与脂肪生成、代谢紊乱、炎症及纤维化等相关,尽管研究不断深入,但目前尚无有效药物可用于治疗NAFLD。NAFLD市场前景巨大,因此针对NAFLD的新药开发迫在眉睫。总结NAFLD治疗靶点及相关在研药物,并重点综述近期临床数据积极的NAFLD新药研发进展,以期为本领域研究提供最新的研究资料和参考。

Nonalcoholic fatty liver disease(NAFLD),which can lead to end-stage liver illnesses like cirrhosis and liver cancer,is emerging as the most common chronic liver disease in the world.NAFLD is a multisystem metabolic disorder that is closely associated with illnesses of extrahepatic organs.Its pathophysiology is complicated and linked to fibrosis,inflammation,metabolic problems,and lipogenesis,among other things.No viable medications exist to treat NAFLD despite ongoing,thorough research.The need for new NAFLD medications is urgent given the size of the NAFLD market.In order to give the most recent research data and a resource for researchers,this article reviews the therapeutic targets and related medications in development for NAFLD and focuses on the recent developments of NAFLD drug development with promising clinical data.